IRVINE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- InVitro International (Pink Sheets: IVRO) today reported Fiscal Year 2007 sales of $741,714 and net profit of $69,273. These results compare to Fiscal Year 2006 sales of $608,920 and profits of $15,387, respectively. IVRO President/CEO, W. Richard Ulmer said: "We are delighted to report our highest company sales since 1996, an advance of 21% over the prior year; an all time high in profits, as well as profits for the 4th year in our last five; a near doubling of sales in Latin America to more than 12% of company sales; approximately a two-thirds increase in European sales, sparked in great part by our wonderful investing Italian partner, ResPharma/INT.E.G.RA; and finally our U.S. sales advanced more than 18%. When we examine sales by technology, it was pleasing to see Irritection(R) advance nearly 30% while Corrositex jumped 16% following its formal European acceptance published late in 2006. Similar Regulatory acceptance for Irritection(R) is progressing per normal government review schedules." On Wednesday, December 12 at noon PST, President, Rich Ulmer, http://www.invitrointl.com/ will be interviewed on http://www.wallst.net/ regarding these results and many other subjects in the non-animal testing methods business. This press release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance. DATASOURCE: InVitro International CONTACT: W. Richard Ulmer of InVitro International, 1-800-2-INVITRO Web site: http://www.invitrointl.com/

Copyright